Report Overview

The United Kingdom Metabolic Disorders market is USD XXs billion in 2019 and it is growing at a CAGR of 7.2% during the forecast period (2019-2028).

As per the National Health Service, UK, 28.7% of adults in England were obese and 35.6% were overweight. Of obese adults, nearly 1 in 8 are morbidly obese (3.6% of all adults). Diabetes is a form of metabolic disorder, which results in an increasing demand for diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others. Rosiglitazone (Avandia) is intended for use as an adjunct to exercise and diet to improve glycemic control in adults suffering from type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR)-responsive genes that participate in the regulation of fatty acid metabolism.



Market Drivers

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile for the UK population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. The introduction of patient assistance programs to provide treatment for a range of metabolic disorders and the rise in awareness about the availability of therapeutics for these diseases drive the market growth. Moreover, the advancement in technology and increase in funding for the development of novel therapeutic approaches from government and non-government organizations are expected to further boost the market. Some of the commonly available treatment procedures for metabolic disorders include a range of therapeutic medications such as vitamin, mineral, physical therapy, and surgeries.